FR2883182B1 - Composition de vitamines utiles dans le traitement des maladies oculaires - Google Patents

Composition de vitamines utiles dans le traitement des maladies oculaires

Info

Publication number
FR2883182B1
FR2883182B1 FR0502582A FR0502582A FR2883182B1 FR 2883182 B1 FR2883182 B1 FR 2883182B1 FR 0502582 A FR0502582 A FR 0502582A FR 0502582 A FR0502582 A FR 0502582A FR 2883182 B1 FR2883182 B1 FR 2883182B1
Authority
FR
France
Prior art keywords
treatment
composition useful
ocular diseases
vitamin composition
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0502582A
Other languages
English (en)
Other versions
FR2883182A1 (fr
Inventor
Veronique Levert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0502582A priority Critical patent/FR2883182B1/fr
Application filed by Novartis AG filed Critical Novartis AG
Priority to CA002599468A priority patent/CA2599468A1/fr
Priority to PCT/EP2006/002303 priority patent/WO2006097267A1/fr
Priority to AU2006224771A priority patent/AU2006224771A1/en
Priority to MX2007011315A priority patent/MX2007011315A/es
Priority to KR1020077021151A priority patent/KR20070112389A/ko
Priority to EP06707544A priority patent/EP1865948A1/fr
Priority to BRPI0608512-1A priority patent/BRPI0608512A2/pt
Priority to RU2007137988/15A priority patent/RU2007137988A/ru
Priority to JP2008501216A priority patent/JP2008533075A/ja
Priority to CNA2006800071528A priority patent/CN101132790A/zh
Publication of FR2883182A1 publication Critical patent/FR2883182A1/fr
Application granted granted Critical
Publication of FR2883182B1 publication Critical patent/FR2883182B1/fr
Priority to AU2010201804A priority patent/AU2010201804A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0502582A 2005-03-16 2005-03-16 Composition de vitamines utiles dans le traitement des maladies oculaires Active FR2883182B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR0502582A FR2883182B1 (fr) 2005-03-16 2005-03-16 Composition de vitamines utiles dans le traitement des maladies oculaires
RU2007137988/15A RU2007137988A (ru) 2005-03-16 2006-03-14 Витаминные смеси
AU2006224771A AU2006224771A1 (en) 2005-03-16 2006-03-14 Vitamin mixtures
MX2007011315A MX2007011315A (es) 2005-03-16 2006-03-14 Mezclas de vitaminas.
KR1020077021151A KR20070112389A (ko) 2005-03-16 2006-03-14 비타민 혼합물
EP06707544A EP1865948A1 (fr) 2005-03-16 2006-03-14 Melanges vitamines
CA002599468A CA2599468A1 (fr) 2005-03-16 2006-03-14 Melanges vitamines
PCT/EP2006/002303 WO2006097267A1 (fr) 2005-03-16 2006-03-14 Melanges vitamines
JP2008501216A JP2008533075A (ja) 2005-03-16 2006-03-14 ビタミン混合物
CNA2006800071528A CN101132790A (zh) 2005-03-16 2006-03-14 维生素混合物
BRPI0608512-1A BRPI0608512A2 (pt) 2005-03-16 2006-03-14 misturas de vitaminas
AU2010201804A AU2010201804A1 (en) 2005-03-16 2010-05-05 Vitamin mixtures

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0502582A FR2883182B1 (fr) 2005-03-16 2005-03-16 Composition de vitamines utiles dans le traitement des maladies oculaires

Publications (2)

Publication Number Publication Date
FR2883182A1 FR2883182A1 (fr) 2006-09-22
FR2883182B1 true FR2883182B1 (fr) 2008-02-15

Family

ID=35159734

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0502582A Active FR2883182B1 (fr) 2005-03-16 2005-03-16 Composition de vitamines utiles dans le traitement des maladies oculaires

Country Status (11)

Country Link
EP (1) EP1865948A1 (fr)
JP (1) JP2008533075A (fr)
KR (1) KR20070112389A (fr)
CN (1) CN101132790A (fr)
AU (2) AU2006224771A1 (fr)
BR (1) BRPI0608512A2 (fr)
CA (1) CA2599468A1 (fr)
FR (1) FR2883182B1 (fr)
MX (1) MX2007011315A (fr)
RU (1) RU2007137988A (fr)
WO (1) WO2006097267A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009512626A (ja) * 2005-09-08 2009-03-26 ディーエスエム アイピー アセッツ ビー．ブイ． 加齢性黄斑変性症を処置又は予防する方法
JP2008239528A (ja) * 2007-03-26 2008-10-09 Lion Corp 目及び脳機能改善剤
WO2009098186A1 (fr) * 2008-02-04 2009-08-13 Novartis Ag Composés organiques
WO2011095837A1 (fr) * 2010-02-02 2011-08-11 Soluciones Extractivas Alimentarias, S.L. Solutex Esters éthyliques de l'acide docosahexaénoïque et/ou leurs dérivés pour la prévention et/ou le traitement de la dégénérescence maculaire liée à l'âge
CN102726734A (zh) * 2012-07-12 2012-10-17 邓群洲 一种富含叶黄素和多种维生素的软胶囊及其制备方法
AU2016386385B2 (en) * 2016-01-15 2020-05-21 Novex Science Pte Limited Stable and palatable composition of vitamin C and zinc lozenge tablets
CN110559314A (zh) * 2018-05-17 2019-12-13 中港大富科技有限公司 一种保护视力的组合物
FR3094209B1 (fr) * 2019-03-25 2021-03-12 Sophie Hvostoff Composition de desmodium et de chrome trivalent et utilisation a visee oculaire
CN111943268A (zh) * 2020-08-19 2020-11-17 成都虹冉生物科技有限公司 从生产维生素k3的废液中回收铬的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033494A1 (fr) * 1997-02-04 1998-08-06 Kosbab John V Compositions et procedes destines a la prevention et au traitement de maladies degeneratives vasculaires
US6582721B1 (en) * 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
AU2002221934A1 (en) * 2000-12-16 2002-06-24 Aventis Pharma Deutschland Gmbh Health promoting compositions
EP1214893A1 (fr) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Compositions pour améliorer la santé
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
EP1635842A4 (fr) * 2003-06-20 2007-04-04 Alcon Inc Traitement de la dmla par combinaison d'ingredients

Also Published As

Publication number Publication date
BRPI0608512A2 (pt) 2010-01-05
CN101132790A (zh) 2008-02-27
AU2010201804A1 (en) 2010-05-27
EP1865948A1 (fr) 2007-12-19
CA2599468A1 (fr) 2006-09-21
MX2007011315A (es) 2007-11-08
RU2007137988A (ru) 2009-04-27
WO2006097267A1 (fr) 2006-09-21
JP2008533075A (ja) 2008-08-21
FR2883182A1 (fr) 2006-09-22
KR20070112389A (ko) 2007-11-23
AU2006224771A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
FR2883182B1 (fr) Composition de vitamines utiles dans le traitement des maladies oculaires
DE602005011279D1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
IL222879A (en) Peptides and their use in the treatment and diagnosis of diseases and pharmaceutical preparations containing them
EP1893216A4 (fr) Methodes et preparations pour le traitement de troubles oculaires
EP1758595A4 (fr) Utilisation de conjugues lipidiques dans le traitement de maladies
HK1175718A1 (zh) 利用補體途徑抑制劑治療眼部疾病
FR2887450B1 (fr) Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
EP2094281A4 (fr) Utilisation de conjugués lipidiques dans le traitement de maladies ou de troubles oculaires
EP1744740A4 (fr) Derives d'acide phenoxyalkycarboxylique pour le traitement des maladies inflammatoires
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
EP1753445A4 (fr) Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
PL2056863T3 (pl) Leczenie chorób oczu
PL1881824T3 (pl) Zastosowanie triglicerydów kwasu dokozaheksaenowego w leczeniu chorób nowotworowych
FR2899476B1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
GB0523961D0 (en) The treatment of ophthalmic diseases
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
BRPI0811572A2 (pt) Uso de compostos imunomoduladores no tratamento de doenças alérgicas
FR2933976B1 (fr) Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives
EP1865952A4 (fr) Compositions contenant des histamines pour le traitement des allergies
BRPI0719997A2 (pt) Uso de epotilonas no tratamento de osteoporose e doenças relacionadas

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 16

TP Transmission of property

Owner name: ALCON INC., CH

Effective date: 20200430

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20